Notice of Change to Expansion of Eligibility of Optional Companion Applications for CTSA Program Funding Opportunities: PAR-21-293 (UM1), PAR-21-340 (RC2), PAR-21-339 (R25), PAR-21-338 (T32), and PAR-21-337 (T32)
Notice Number:
NOT-TR-22-008

Key Dates

Release Date:

November 15, 2021

Related Announcements

PAR-21-293 - Clinical and Translational Science Award (UM1 Clinical Trial Optional)
PAR-21-340 - Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Not Allowed)
PAR-21-339 - Limited Competition: NCATS Clinical and Translational Science Award (CTSA) Program Research Education Grants Programs (R25 - Clinical Trial Not Allowed)
PAR-21-338 - Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (T32 Clinical Trial Not Allowed)
PAR-21-337- Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (T32 Clinical Trial Not Allowed)
NOT-TR-22-007 - Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (T32 Clinical Trial Not Allowed)

Issued by

National Center for Advancing Translational Sciences (NCATS)

Purpose

The purpose of this Notice is to alert potential applicants to expansion of the eligibility of the following companion optional applications associated with applications submitted to PAR-21-293, Clinical and Translational Science Award (UM1 Clinical Trial Optional):

PAR-21-340 - Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Not Allowed)
PAR-21-339 - Limited Competition: NCATS Clinical and Translational Science Award (CTSA) Program Research Education Grants Programs (R25 - Clinical Trial Not Allowed)
PAR-21-338 - Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (T32 Clinical Trial Not Allowed)
PAR-21-337 - Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (T32 Clinical Trial Not Allowed)

Companion optional applications may be submitted in accordance with the applicable FOA application submission dates under the following scenarios:

  • concurrently with the UM1
  • while the UM1 application is under review consideration
  • after the UM1 application is funded
  • while the UM1 is under consideration for funding

While optional companion applications may be submitted concurrently with the UM1 application or at any time the submitted UM1 new or resubmission application remains active, optional companion applications will only be awarded if the UM1 is awarded.

As a reminder, NIH will send centralized automated correspondence to applicant organizations notifying them of NIH’s intent not to fund the indicated applications. A consolidated email, listing the applications which NIH does not intend to fund, will be sent by the NIH eRA system to the authorized organization representative (AOR) and signing official (SO) listed in the grant application, and the Notice of Award email address listed in the applicant’s Institutional Profile. The email will be sent approximately 14 months after the application’s council date.

In addition to receiving official email correspondence for NIH, applicants can determine whether the Unfunded Application Notification has been sent for a specific grant application in the eRA Commons. Please also note that the funding decisions indicated in the correspondence are specific to the applications included in the email and have no impact on subsequent submissions, including resubmissions. NIH’s application submission/resubmission policy is outlined in NOT-OD-18-197.

Thus, UM1s that are not selected for funding after a term of 14 months after Council review will generally be considered ineligible for funding and companion optional applications to the UM1 will no longer be eligible to be submitted and will not be accepted. Note that the 14-month window for funding eligibility also applies to resubmitted applications; that is, receipt of a resubmitted application constitutes the starting point for the 14-month eligibility window.

For illustrative purposes, example timelines of submission of a CTSA suite of applications (UM1, required K12, and companion optional applications) are provided:

Example 1:

  • Required applications:
    • UM1 and K12 (required companion application) submitted May 13, 2022 (January 2023 Council). These applications will be under consideration until May 2024 (for up to 14 months after Council).
  • Optional companion applications:
    • T32 (predoc) and T32 (postdoc) are submitted September 16, 2022
    • R25 is submitted January 13, 2023
    • One RC2 application submitted January 13, 2023
    • One RC2 application submitted May 17, 2024 (This is the last receipt date that any companion application may be eligible because the next receipt date is September 13, 2024, which is after the 14-month window that the UM1 could be under consideration for funding.)

Example 2:

  • Required applications:
    • UM1 and K12 (required companion application) submitted September 16, 2022 (May 2023 Council). These applications will be under consideration until September 2024 (for up to 14 months after Council).
  • Optional companion application:
    • T32 (predoc) submitted September 15, 2023

Eligibility Window:

UM1 and K12 Application Due Date

Advisory Council Review

Last Receipt Date for Companion Optional Applications

May 13, 2022

January 2023

May 17, 2024

September 16, 2022

May 2023

September 13, 2024


All other aspects of these Funding Opportunity Announcements remain unchanged.

Inquiries

Please direct all inquiries to:

PAR-21-293, UM1 Research Project with Complex Structure Cooperative Agreement
Erica Rosemond, Ph.D.
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-594-8927
Email: CTSAFOAQuestions@mail.nih.gov

PAR-21-340, RC2 High Impact Research and Research Infrastructure Programs
Pablo Cure, M.D., M.P.H.
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-827-2014
Email: CTSAFOAQuestions@mail.nih.gov

PAR-21-339, R25 Education Projects
Jamie Doyle, Ph.D.
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-402-0403
Email: CTSATrainingFOAsQuestions@mail.nih.gov

PAR-21-338, T32 Institutional National Research Service Award (NRSA)-postdoctoral
Mercedes Rubio, Ph.D.
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-480-8957
Email: CTSATrainingFOAsQuestions@mail.nih.gov

PAR-21-337, T32 Institutional National Research Service Award (NRSA)--predoctoral
Mercedes Rubio, Ph.D.
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-480-8957
Email: CTSATrainingFOAsQuestions@mail.nih.gov